197 related articles for article (PubMed ID: 23284040)
1. High familial risk in nodular lymphocyte-predominant Hodgkin lymphoma.
Saarinen S; Pukkala E; Vahteristo P; Mäkinen MJ; Franssila K; Aaltonen LA
J Clin Oncol; 2013 Mar; 31(7):938-43. PubMed ID: 23284040
[TBL] [Abstract][Full Text] [Related]
2. The incidence of lymphoma in first-degree relatives of patients with Hodgkin disease and non-Hodgkin lymphoma: results and limitations of a registry-linked study.
Paltiel O; Schmit T; Adler B; Rachmilevitz EA; Polliack A; Cohen A; Haim N; Shachar MB; Epelbaum R; Barchana M; Cohen R; Ben Yehuda D
Cancer; 2000 May; 88(10):2357-66. PubMed ID: 10820359
[TBL] [Abstract][Full Text] [Related]
3. Epidemiology of classic and nodular lymphocyte predominant hodgkin lymphoma in Finland in 1996-2015.
Juntikka T; Malila N; Ylöstalo T; Merikivi M; Jyrkkiö S
Acta Oncol; 2020 May; 59(5):574-581. PubMed ID: 31910680
[No Abstract] [Full Text] [Related]
4. Familial aggregation of Hodgkin lymphoma and related tumors.
Goldin LR; Pfeiffer RM; Gridley G; Gail MH; Li X; Mellemkjaer L; Olsen JH; Hemminki K; Linet MS
Cancer; 2004 May; 100(9):1902-8. PubMed ID: 15112271
[TBL] [Abstract][Full Text] [Related]
5. Characteristics and outcomes of patients with nodular lymphocyte-predominant Hodgkin lymphoma versus those with classical Hodgkin lymphoma: a population-based analysis.
Gerber NK; Atoria CL; Elkin EB; Yahalom J
Int J Radiat Oncol Biol Phys; 2015 May; 92(1):76-83. PubMed ID: 25863756
[TBL] [Abstract][Full Text] [Related]
6. Family history of hematopoietic malignancy and risk of lymphoma.
Chang ET; Smedby KE; Hjalgrim H; Porwit-MacDonald A; Roos G; Glimelius B; Adami HO
J Natl Cancer Inst; 2005 Oct; 97(19):1466-74. PubMed ID: 16204696
[TBL] [Abstract][Full Text] [Related]
7. Cancer risk in the Swiss HIV Cohort Study: associations with immunodeficiency, smoking, and highly active antiretroviral therapy.
Clifford GM; Polesel J; Rickenbach M; Dal Maso L; Keiser O; Kofler A; Rapiti E; Levi F; Jundt G; Fisch T; Bordoni A; De Weck D; Franceschi S;
J Natl Cancer Inst; 2005 Mar; 97(6):425-32. PubMed ID: 15770006
[TBL] [Abstract][Full Text] [Related]
8. Cancer risks among relatives of children with Hodgkin and non-Hodgkin lymphoma.
Pang D; Alston RD; Eden TO; Birch JM
Int J Cancer; 2008 Sep; 123(6):1407-10. PubMed ID: 18561317
[TBL] [Abstract][Full Text] [Related]
9. Risk of familial classical Hodgkin lymphoma by relationship, histology, age, and sex: a joint study from five Nordic countries.
Kharazmi E; Fallah M; Pukkala E; Olsen JH; Tryggvadottir L; Sundquist K; Tretli S; Hemminki K
Blood; 2015 Oct; 126(17):1990-5. PubMed ID: 26311361
[TBL] [Abstract][Full Text] [Related]
10. Nodular lymphocyte predominant Hodgkin lymphoma.
Lee AI; LaCasce AS
Oncologist; 2009 Jul; 14(7):739-51. PubMed ID: 19605845
[TBL] [Abstract][Full Text] [Related]
11. Nodular lymphocyte-predominant Hodgkin lymphoma: cytopathologic correlates on fine-needle aspiration.
Subhawong AP; Ali SZ; Tatsas AD
Cancer Cytopathol; 2012 Aug; 120(4):254-60. PubMed ID: 22367911
[TBL] [Abstract][Full Text] [Related]
12. Second lymphomas and other malignant neoplasms in patients with mycosis fungoides and Sezary syndrome: evidence from population-based and clinical cohorts.
Huang KP; Weinstock MA; Clarke CA; McMillan A; Hoppe RT; Kim YH
Arch Dermatol; 2007 Jan; 143(1):45-50. PubMed ID: 17224541
[TBL] [Abstract][Full Text] [Related]
13. Population-based study of Hodgkin's lymphoma in Kuwait.
Alshemmari S; Sajnani KP; Refaat S; Albassami A
Gulf J Oncolog; 2011 Jan; (9):20-6. PubMed ID: 21177205
[TBL] [Abstract][Full Text] [Related]
14. Methods for testing familial aggregation of diseases in population-based samples: application to Hodgkin lymphoma in Swedish registry data.
Pfeiffer RM; Goldin LR; Chatterjee N; Daugherty S; Hemminki K; Pee D; X LI; Gail MH
Ann Hum Genet; 2004 Sep; 68(Pt 5):498-508. PubMed ID: 15469426
[TBL] [Abstract][Full Text] [Related]
15. Transformation to aggressive lymphoma in nodular lymphocyte-predominant Hodgkin's lymphoma.
Al-Mansour M; Connors JM; Gascoyne RD; Skinnider B; Savage KJ
J Clin Oncol; 2010 Feb; 28(5):793-9. PubMed ID: 20048177
[TBL] [Abstract][Full Text] [Related]
16. Highly recurrent mutations of SGK1, DUSP2 and JUNB in nodular lymphocyte predominant Hodgkin lymphoma.
Hartmann S; Schuhmacher B; Rausch T; Fuller L; Döring C; Weniger M; Lollies A; Weiser C; Thurner L; Rengstl B; Brunnberg U; Vornanen M; Pfreundschuh M; Benes V; Küppers R; Newrzela S; Hansmann ML
Leukemia; 2016 Apr; 30(4):844-53. PubMed ID: 26658840
[TBL] [Abstract][Full Text] [Related]
17. Risk of non-Hodgkin's lymphoma and family history of lymphatic, hematologic, and other cancers.
Chatterjee N; Hartge P; Cerhan JR; Cozen W; Davis S; Ishibe N; Colt J; Goldin L; Severson RK
Cancer Epidemiol Biomarkers Prev; 2004 Sep; 13(9):1415-21. PubMed ID: 15342441
[TBL] [Abstract][Full Text] [Related]
18. Intranodular clusters of activated cells with T follicular helper phenotype in nodular lymphocyte predominant Hodgkin lymphoma: a pilot study of 32 cases from Finland.
Nathwani BN; Vornanen M; Winkelmann R; Kansal R; Doering C; Hartmann S; Hansmann ML
Hum Pathol; 2013 Sep; 44(9):1737-46. PubMed ID: 23684509
[TBL] [Abstract][Full Text] [Related]
19. Does functional imaging distinguish nodular lymphocyte-predominant hodgkin lymphoma from T-cell/histiocyte-rich large B-cell lymphoma?
Barber NA; Loberiza FR; Perry AM; Bast M; Holdeman KP; Esfahane AB; Weisenburger DD; Vose J; Bierman P; Armitage JO; Bociek RG
Clin Lymphoma Myeloma Leuk; 2013 Aug; 13(4):392-7. PubMed ID: 23773450
[TBL] [Abstract][Full Text] [Related]
20. Prophylactic Oophorectomy: Reducing the U.S. Death Rate from Epithelial Ovarian Cancer. A Continuing Debate.
Piver MS
Oncologist; 1996; 1(5):326-330. PubMed ID: 10388011
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
